SUNPHARMA

Sun Pharma : Co. Gets DCGI Nod for Generic Semaglutide in India • 💊 Regulatory Approval Secured: DCGI approved Sun Pharma to manufacture & market generic semaglutide injection for chronic weight management in adults • ⏳ Launch Post Patent Expiry: Product to be launched after semaglutide patent expiry in India, limiting near-term revenue but unlocking large future opportunity • 📈 Big Obesity & Diabetes Opportunity: Targets India’s rapidly growing obesity & cardiometabolic market, supported by strong clinical demand • 🧪 Strong Clinical Backing: Approval based on successful Phase III Indian clinical trials, enhancing credibility and adoption potential • 🏭 Multiple Dosage Strengths: Product (brand: Noveltreat) to be available in 5 dose strengths via easy-to-use prefilled pens 🟢 Impact: Positive Positions Sun Pharma as a key domestic GLP-1 player, strengthening its cardiometabolic portfolio and long-term growth prospects once patent barriers lift.